Evidence map›Paper›PMID 41477323›Full record

ArticleActa pharmaceutica Sinica. B2025

Development of a novel

Jian Rong, Chunyu Zhao, Ahmad F Chaudhary, Tim Ware, Richard S Van, Yinlong Li, Erick R Calderon Leon, Vivi Dang, Jiahui Chen, Zhiwei Xiao and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Development of NovelACS pharmacology & translational science · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jian RongDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Chunyu ZhaoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Ahmad F ChaudharyDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Tim WareThe Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Richard S VanDepartment of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA.
Yinlong LiDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Erick R Calderon LeonDepartment of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA.
Vivi DangDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA.
Jiahui ChenDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Zhiwei XiaoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Xin ZhouDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Wei ZhangDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Chunyang BiDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Kuo ZhangDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Jimmy S PatelDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Yihan ShaoDepartment of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA.
Chongzhao RanAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA.
Ludovic CollinF. Hoffmann-La Roche Ltd. Roche. Innovation Center Basel, Switzerland by Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel 4070, Switzerland.
Achi HaiderDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.
Benjamin F CravattThe Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Steven H LiangDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA.

Funding

micro-PET/CT system for preclinical molecular imagingS10OD034326 · OD · EMORY UNIVERSITY · PI LIANG, STEVEN H · 2024 to 2024
$600k
NIH HHS S10 OD034326
6 · The paper itself

Abstract

Monoacylglycerol lipase (MAGL) constitutes a crucial serine hydrolase within the endocannabinoid system, which has been suggested as a potential therapeutic target for the treatment of various neurodegenerative disorders. While MAGL inhibitors have entered the clinical arena, a highly selective and MAGL-specific positron emission tomography (PET) ligand holds promise to significantly facilitate clinical drug development by allowing the quantification of MAGL levels and the assessment of target occupancy in patients. Accordingly, this study aimed to develop a new series of reversible MAGL inhibitor candidates, based on a piperazinyl azetidine diamide scaffold. Compound

Indexed as

MAGLMonoacylglycerol lipasePETSerine hydrolase

Identifiers

PMID41477323
PMCPMC12750168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.